Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 03:00 source : Alteritytherapeutics.com save search
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
Published: 2023-04-25 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.07%
natural sensor therapeutics study
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
Published: 2023-04-27 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: -1.79%
H: 3.64%
C: 0.36%
fy23 report flow
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Published: 2023-01-09 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: 1.46%
H: 2.22%
C: -2.82%
ath434 treatment system trial therapeutics
Chairman’s Address 2022 Annual General Meeting
Published: 2022-11-11 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: -1.15%
H: 8.03%
C: 7.98%
meeting
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
Published: 2022-11-07 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: 2.78%
H: 1.08%
C: 1.08%
meeting therapeutics presentation study
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Published: 2022-10-13 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: -4.1%
H: 6.41%
C: 6.34%
ath434 treatment system australia trial therapeutics phase 2
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
Published: 2022-07-22 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: -4.58%
H: 7.57%
C: 4.83%
fy22 report flow
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference
Published: 2022-05-26 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: 4.14%
H: 3.09%
C: -1.38%
conference therapeutics house
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
Published: 2022-04-27 (Crawled : 03:00) - alteritytherapeutics.com
ATHE | $2.15 6.97% 6.51% 27K
|
Health Technology
|
| O: 0.7%
H: 2.6%
C: -2.0%
ath434 trial therapeutics authorization phase 2
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.